Literature DB >> 9580110

Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet.

J C Escolà-Gil1, A Marzal-Casacuberta, J Julve-Gil, B Y Ishida, J Ordóñez-Llanos, L Chan, F González-Sastre, F Blanco-Vaca.   

Abstract

We report on the effect of human apolipoprotein (apo) A-II transgene expression on atherosclerosis susceptibility in two transgenic lines (25.3 and 11.1) whose plasma human apoA-II concentrations (approximately 23 and 96 mg/dl, respectively) span the normal range in humans. After 9 months of an atherogenic diet, 25.3 and 11.1 transgenic mice developed aortic atherosclerotic lesions that were approximately 1.7- and 7-fold, respectively, more extensive than those of non-transgenic control mice. However, there was no difference in the area of atherosclerosis of transgenic and control mice when fed a regular chow diet This contrasts with the findings in murine apoA-II transgenic mice and provides evidence of a species-specific characteristic that could be of relevance with respect to the high fat intake diets common in most industrialized countries. A possible mechanism of the pro-atherogenic action of human apoA-II could be the inhibition of reverse cholesterol transport and, in support of this, we observed an impairment of apoA-I-HDL particle interconversion in the plasma of 11.1 transgenic mice caused, at least in part, by a marked decrease in the endogenous lecithin:cholesterol acyltransferase activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580110

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  19 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Anti-oxidant properties of high-density lipoprotein and atherosclerosis.

Authors:  Eugene A Podrez
Journal:  Clin Exp Pharmacol Physiol       Date:  2010-03-30       Impact factor: 2.557

Review 3.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

Review 4.  HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.

Authors:  Robert S Rosenson; H Bryan Brewer; Philip J Barter; Johan L M Björkegren; M John Chapman; Daniel Gaudet; Daniel Seung Kim; Eric Niesor; Kerry-Anne Rye; Frank M Sacks; Jean-Claude Tardif; Robert A Hegele
Journal:  Nat Rev Cardiol       Date:  2017-08-10       Impact factor: 32.419

Review 5.  The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations.

Authors:  L Tian; M Fu
Journal:  J Endocrinol Invest       Date:  2011-06       Impact factor: 4.256

6.  APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations.

Authors:  Dolores Corella; Gina Peloso; Donna K Arnett; Serkalem Demissie; L Adrienne Cupples; Katherine Tucker; Chao-Qiang Lai; Laurence D Parnell; Oscar Coltell; Yu-Chi Lee; Jose M Ordovas
Journal:  Arch Intern Med       Date:  2009-11-09

7.  Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.

Authors:  Yao Wang; Manabu Niimi; Kazutoshi Nishijima; Ahmed Bilal Waqar; Ying Yu; Tomonari Koike; Shuji Kitajima; Enqi Liu; Tomohiro Inoue; Masayuki Kohashi; Yuka Keyamura; Tomohiro Yoshikawa; Jifeng Zhang; Loretta Ma; Xiaohui Zha; Teruo Watanabe; Yujiro Asada; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

8.  Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance.

Authors:  Lawrence W Castellani; Cara N Nguyen; Sarada Charugundla; Michael M Weinstein; Chau X Doan; William S Blaner; Nuttaporn Wongsiriroj; Aldons J Lusis
Journal:  J Biol Chem       Date:  2007-12-26       Impact factor: 5.157

9.  Levels of apolipoprotein A-II in cerebrospinal fluid in patients with neuroborreliosis are associated with lipophagocytosis.

Authors:  L Táborský; P Adam; O Sobek; M Dostál; J Dvoráková; L Dubská
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

10.  Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.

Authors:  Theodore W K Ng; Dick C Chan; P Hugh R Barrett; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2009-10-02       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.